BIN1 reduction ameliorates DNM2 -related Charcot–Marie–Tooth neuropathy
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2419244122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Marie Goret und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institut de génétique, biologie moléculaire et cellulaire, département de Médecine translationnelle et neurogénétique, INSERM U1258, CNRS UMR7104, Un…. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Dynamin II, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: IdEx Unistra, SFRI-STRAT'US, EUR IMCBio.
Abstract (Originalsprache)
Charcot–Marie–Tooth (CMT) disease, the most common inherited neuromuscular disorder, manifests as progressive muscle weakness and peripheral nerve defects. Dominant mutations in DNM2 , encoding the large GTPase dynamin 2, result in CMT without any suggested therapeutic strategy. Different dominant mutations in DNM2 also cause centronuclear myopathy (CNM), and increasing BIN1 (amphiphysin 2), an endogenous modulator of DNM2, rescued CNM in mice. Here, we found that increasing BIN1 level exacerbated the phenotypes of the Dnm2 K562E/+ mouse carrying the most common DNM2 -CMT mutation. Conversely, whole-body reduction of Bin1 expression level, through the generation of Dnm2 K562E/+ mice with heterozygous loss of BIN1, restored motor performance and ameliorated muscle organization and structural defects of peripheral nerves. The rescue of motor defects was maintained at least up to 1 y of age. BIN1 inhibited the GTPase activity of DNM2, and the rescue was driven by an increased activity of the K562E DNM2 -CMT mutant, and a normalization of integrin localization in muscle. Overall, this study highlights BIN1 as a modifier of DNM2 -CMT, and its reduction as a potential therapeutic strategy. It also revealed an opposite pathological mechanism and inverse therapeutic concepts for DNM2 -CMT peripheral neuropathy versus DNM2 -CNM myopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de génétique, biologie moléculaire et cellulaire, département de Médecine translationnelle et neurogénétique, INSERM U1258, CNRS UMR7104, Université de Strasbourg, Illkirch 67404, France.
ORCID-Profile: Marie Goret, Nadia Messaddeq, Jocelyn Laporte
Förderung
- IdEx Unistra
- SFRI-STRAT'US
- EUR IMCBio
- Fondation pour la Recherche Médicale (FRM)
Zitieren
APA
Goret, M., Thomas, M., Edelweiss, E., Messaddeq, N., & Laporte, J. (2025). BIN1 reduction ameliorates DNM2 -related Charcot–Marie–Tooth neuropathy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2419244122
Vancouver
Goret M, Thomas M, Edelweiss E, Messaddeq N, Laporte J. BIN1 reduction ameliorates DNM2 -related Charcot–Marie–Tooth neuropathy. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2419244122
BibTeX
@article{Goret2025,
author = {Goret, Marie and Thomas, Morgane and Edelweiss, Evelina and Messaddeq, Nadia and Laporte, Jocelyn},
title = {BIN1 reduction ameliorates DNM2 -related Charcot–Marie–Tooth neuropathy},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2419244122}
}
EUVIMED